Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : STEM -- StemCells, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Edscharp who wrote (355)	1/24/2000 9:30:00 AM
From: John Soileau	Respond to of 805

Inflazyme has some very cool drug candidates in the pipeline, and a $90 million big pharma development deal. No Phase III yet, so it wouldn't pass your screen, but if they get a potent antiinflammatory out of this with no side effects the stock will be a blockbuster. I bought pretty cheap long ago, not a low risk investment but nice reward if it pans out. CTII though is my real favorite these days. Will be interesting to see how it moves as additional news comes out. I traded some but have a core I ain't letting go of (till a transfer agent makes me exchange them for some big pharma's shares!). John